Q32 Bio (NASDAQ:QTTB) Issues Earnings Results

Q32 Bio (NASDAQ:QTTB) released its earnings results on Tuesday. The company reported $3.65 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $4.71, Zacks reports. The company had revenue of $53.74 million during the quarter.

Q32 Bio Stock Up 15.4%

Shares of NASDAQ:QTTB opened at $6.91 on Thursday. The firm has a market capitalization of $85.02 million, a PE ratio of 3.00 and a beta of 0.14. Q32 Bio has a twelve month low of $1.35 and a twelve month high of $7.10. The company has a 50-day moving average price of $4.14 and a two-hundred day moving average price of $3.09.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Q32 Bio in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Q32 Bio in a report on Friday, January 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $13.00.

More Q32 Bio News

Here are the key news stories impacting Q32 Bio this week:

• Positive Sentiment: Q32 reported a large Q4 2025 beat: EPS $3.65 vs. consensus (‑$1.06) and revenue $53.7M. The company also completed enrollment expansion in the SIGNAL‑AA Phase 2a trial (36‑week topline expected mid‑2026), completed a $10.5M registered direct offering, sold the ADX‑097 asset to Akebia, and reported ~$$48.3M cash plus expected proceeds/milestones — management says this provides runway into Q4 2027. These items explain upside sentiment and improved funding visibility. Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: HC Wainwright materially raised multi‑year EPS forecasts and reiterated a “Buy” rating with a $13 price target — notably FY2030 EPS raised to $0.41 (from $0.11) and FY2029 to $0.16 (from ‑$0.18). The analyst upgrades signal increasing sell‑side confidence in Q32’s pathway to eventual profitability, supporting investor demand.
• Neutral Sentiment: HC Wainwright also published updated quarterly/near‑term estimates for 2026 (Q1–Q4 showing negative EPS between roughly ‑$0.52 and ‑$0.59) — indicating the analyst still expects near‑term losses even as longer‑term estimates improve. The broader consensus full‑year estimate remains deeply negative (about ‑$12.32), so market expectations are uneven.
• Negative Sentiment: Governance and cost risk: a TipRanks piece reports shareholder backlash and rising costs tied to a 2025 stock‑option repricing, which could hurt investor sentiment, create dilution concerns or prompt governance scrutiny. This is a reputational and potential financial headwind. Q32 Bio Faces Governance Backlash and Rising Costs After 2025 Stock Option Repricing

Insider Activity

In other news, CEO Jodie Pope Morrison sold 9,896 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the sale, the chief executive officer owned 89,104 shares of the company’s stock, valued at $401,859.04. The trade was a 10.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 16,706 shares of company stock valued at $75,344 over the last 90 days. Insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of QTTB. Opaleye Management Inc. bought a new stake in Q32 Bio during the 4th quarter valued at $708,000. Geode Capital Management LLC boosted its holdings in shares of Q32 Bio by 19.9% in the fourth quarter. Geode Capital Management LLC now owns 106,113 shares of the company’s stock worth $352,000 after acquiring an additional 17,617 shares during the period. Renaissance Technologies LLC grew its position in shares of Q32 Bio by 110.6% in the fourth quarter. Renaissance Technologies LLC now owns 99,600 shares of the company’s stock valued at $331,000 after purchasing an additional 52,300 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Q32 Bio during the 2nd quarter valued at $69,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of Q32 Bio by 140.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock valued at $73,000 after purchasing an additional 25,953 shares during the period. 31.32% of the stock is owned by institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.